These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 67714)

  • 1. Development of an intravenous gamma-globulin with Fc activities. II. Reconversion of S-sulfonated human gamma-globulin into the original gamma-globulin.
    Masuho Y; Tomibe K; Watanabe T; Fukumoto Y
    Vox Sang; 1977; 32(5):290-5. PubMed ID: 67714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an intravenous gamma-globulin with Fc activities. I. Preparation and characterization of S-sulfonated human gamma-globulin.
    Masuho Y; Tomibe K; Matsuzawa K; Ohtsu A
    Vox Sang; 1977; 32(3):175-81. PubMed ID: 67713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THE ROLE OF DISULFIDE BONDS IN THE COMPLEMENT-FIXING AND PRECIPITATING PROPERTIES OF 7S RABBIT AND SHEEP ANTIBODIES.
    SCHUR PH; CHRISTIAN GD
    J Exp Med; 1964 Oct; 120(4):531-45. PubMed ID: 14212117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOLECULAR BASIS OF PASSIVE SENSITIZATION. II. THE ROLE OF FRAGMENT 3 OF GAMMA-GLOBULIN AND ITS DISULFIDE BONDS IN PASSIVE SENSITIZATION AND COMPLEMENT FIXATION.
    ISHIZAKA K; ISHIZAKA T
    J Immunol; 1964 Jul; 93():59-68. PubMed ID: 14214390
    [No Abstract]   [Full Text] [Related]  

  • 5. Reconstruction of intact gamma-globulin from S-sulfonated gamma-globulin in vivo.
    Masuho Y; Tomibe K; Matsuzawa K; Watanabe T; Ishimoto S
    J Biochem; 1976 Jun; 79(6):1377-9. PubMed ID: 60334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experiences in the use of intravenously injectable tetanus-immune human gamma globulin TIG(i). I. Serum antitoxin levels following injection (author's transl)].
    Ebisawa I; Matsuhashi C; Yamamoto A; Kurosu Y; Otsuka T
    Kansenshogaku Zasshi; 1981 Feb; 55(2):92-100. PubMed ID: 6167649
    [No Abstract]   [Full Text] [Related]  

  • 7. Interaction of S-sulfonated human IgG with human complement and its components.
    Fukumoto Y; Inai S; Nagaki K; Iida K; Yamagami E; Masuho Y; Watanabe T
    J Biochem; 1977 Oct; 82(4):955-60. PubMed ID: 336617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous gamma globulin. Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons.
    Janeway CA; Merler E; Rosen FS; Salmon S; Crain JD
    N Engl J Med; 1968 Apr; 278(17):919-23. PubMed ID: 4171301
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prophylaxis and therapy with gamma globulin. General characterization and clinical use of gamma globulin preparations].
    Barandun S; Skvaril F; Morell A
    Schweiz Med Wochenschr; 1976 Apr; 106(16):533-42. PubMed ID: 62393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial of sulfonated immunoglobulin preparation for intravenous administration. I. Replacement therapy for primary immunodeficiency syndromes.
    Kobayashi N; Gohya N; Matsumoto S
    Eur J Pediatr; 1981 May; 136(2):159-65. PubMed ID: 6164554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application.
    Barandun S; Castel V; Makula MF; Morell A; Plan R; Skvaril F
    Vox Sang; 1975; 28(3):157-75. PubMed ID: 47211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of antitoxin and antibacterial activity of human preparations of normal immunoglobulin. I. Level of tetanus antitoxin in preparations of IMIG and IVIG].
    Zakrzewska A; Rymkiewicz D
    Przegl Epidemiol; 1995; 49(4):381-4. PubMed ID: 8868196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical experiences in the use of intravenously injectable tetanus-immune human gamma globulin TIG(i). II. Clinical and side effects (author's transl)].
    Ebisawa I; Kurosu Y; Otsuka T; Matsuhashi C; Yamamoto A
    Kansenshogaku Zasshi; 1981 Feb; 55(2):101-8. PubMed ID: 6167648
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous gamma globulin. I. Background.
    Baumgarten W
    Vox Sang; 1967 Jul; 13(1):84-5. PubMed ID: 4166593
    [No Abstract]   [Full Text] [Related]  

  • 15. [Human antitetanus gamma globulins].
    Herzog F; Gaiffe M; Badillet M
    Presse Med (1893); 1969 Feb; 77(6):207-8. PubMed ID: 4182144
    [No Abstract]   [Full Text] [Related]  

  • 16. [Measurement of the anti-complementary activity of gamma-globulin preparations for intravenous administration].
    Malgras J; Hauptmann G; Zorn JJ; Waitz R
    Rev Fr Transfus; 1970 Jun; 13(2):173-80. PubMed ID: 4100946
    [No Abstract]   [Full Text] [Related]  

  • 17. The preparation of plasmin treated immune serum globulin for intravenous use.
    Sgouris JT
    Vox Sang; 1967 Jul; 13(1):71-84. PubMed ID: 4166592
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experimental analysis of the complement-binding activity of gamma-globulin].
    Ternovoĭ AP; Skrigan ER
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Aug; (8):95-9. PubMed ID: 72470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EXPERIMENTAL GLOMERULONEPHRITIS. IV. PARTICIPATION OF COMPLEMENT IN NEPHROTOXIC NEPHRITIS.
    UNANUE E; DIXON FJ
    J Exp Med; 1964 Jan; 119(6):965-82. PubMed ID: 14176294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on the elimination of fermentally disintegrated gamma globulin from the blood plasma].
    Mai K; Bläker F
    Z Immunitatsforsch Exp Klin Immunol; 1971 Aug; 142(2):173-82. PubMed ID: 4105637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.